CYP1A2 rs1799834: Genetic Variation and Caffeine Metabolism
The rs1799834 polymorphism is a common non-coding variant located within the CYP1A2 gene on chromosome 15. The CYP1A2 enzyme is primarily responsible for the hepatic clearance of dietary caffeine and various clinical medications. Research suggests this variant may modulate enzyme expression and inducibility, contributing to individual differences in metabolic breakdown, although overall clinical evidence remains limited.
What each genotype means
Typical baseline CYP1A2 activity
You carry two copies of the ancestral A allele at this CYP1A2 locus, which is associated with typical baseline enzyme expression and standard clearance of substrate compounds such as caffeine and certain medications. Published findings for this individual single nucleotide variant are limited, and overall metabolic rate depends heavily on broader haplotypes and lifestyle factors like smoking. If you have questions regarding the breakdown of specific pharmaceuticals metabolized by CYP1A2, consult your doctor or pharmacist.
Carried by approximately 45% to 50% of individuals globally, though frequencies vary modestly by ancestry.
Intermediate enzyme inducibility
You carry one copy of the G alternative allele, which has been studied in candidate gene analyses for subtle variations in CYP1A2 inducibility and the clearance of caffeine. The clinical evidence evaluating this variant alone is limited and mixed, with most observed metabolic variation explained by broader multi-SNP CYP1A2 star alleles. If you are taking prescription medications cleared by CYP1A2, discuss proper dosing and management with your clinician or pharmacist.
Carried by approximately 40% to 45% of individuals worldwide, representing a common heterozygous profile across most populations.
Altered CYP1A2 inducibility
You carry two copies of the G alternative allele, a pattern evaluated in pharmacogenetic studies for potential differences in CYP1A2 enzyme activity and responsiveness to dietary inductors. Evidence for significant isolated effects of this genotype remains limited, and it generally occurs within larger haplotypes that dictate caffeine and drug clearance. For any guidance concerning medications metabolized by CYP1A2, review your therapy with a healthcare provider or pharmacist.
Carried by roughly 5% to 10% of individuals in global populations.
Variant Details and Genomic Location
The single nucleotide polymorphism rs1799834 resides in the CYP1A2 locus on the long arm of chromosome 15 (15q24.1). In the human genome, this position primarily reflects an exchange between cytosine (C) and thymine (T) alleles. Because it is positioned within a non-coding region of the gene, it does not alter the underlying amino acid sequence of the resulting protein. Instead, non-coding variants in CYP1A2 typically function by influencing regulatory elements, such as promoter activity, transcription factor binding sites, or intron-mediated splicing efficiency. Variants in this gene are frequently studied in linkage disequilibrium with other regulatory SNPs, meaning rs1799834 is often inherited as part of larger extended haplotypes that collectively dictate hepatic enzyme levels.
Biological Role of the CYP1A2 Enzyme
CYP1A2 codes for Cytochrome P450 Family 1 Subfamily A Member 2, a major monooxygenase expressed primarily in the liver. This enzyme accounts for approximately 13% to 15% of total hepatic cytochrome P450 content and is responsible for metabolizing roughly 95% of consumed caffeine into paraxanthine, theobromine, and theophylline. Beyond dietary xanthines, CYP1A2 is an essential pathway for biotransforming several prescription drugs, including the antidepressant fluvoxamine, antipsychotics like olanzapine and clozapine, and the muscle relaxant tizanidine. The expression of CYP1A2 is uniquely dynamic; it is heavily influenced by environmental factors such as tobacco smoke, charbroiled foods, and cruciferous vegetables, which induce higher enzyme activity through the aryl hydrocarbon receptor pathway.
Scientific Research and Clinical Evidence
Scientific investigations into rs1799834 primarily focus on its modulating role in CYP1A2 inducibility and baseline metabolic rates. Pharmacogenetic studies evaluate whether carriers of the minor allele experience altered rates of xenobiotic clearance or distinct responses to environmental inducers. While some association studies observe modest differences in caffeine clearance rates or cardiovascular metrics linked to coffee consumption, the evidence strength for rs1799834 itself remains classified as limited. In pharmacogenetics databases such as PharmGKB, broader regulatory markers like rs762551 (defining the CYP1A2*1F haplotype) receive substantially more clinical focus. Many associations observed with rs1799834 may be secondary consequences of linkage with other established regulatory polymorphisms rather than independent causal mechanisms.
Population Patterns and Genetic Diversity
The rs1799834 single nucleotide polymorphism is relatively common across global populations, displaying an overall minor allele frequency (MAF) of approximately 0.30. However, the distribution of the C and T alleles varies among continental ancestries according to large-scale sequencing datasets like gnomAD. The variant is observed regularly in European, African, and East Asian cohorts, though the specific frequencies and the degree of linkage disequilibrium with adjacent CYP1A2 functional alleles differ. Because haplotype structures vary by ancestral background, the functional implication of carrying a specific genotype at rs1799834 can depend heavily on which other regulatory variants are co-inherited on the same chromosome.
Practical Considerations and Healthcare Context
Understanding your rs1799834 genotype provides interesting educational context regarding how your body may process dietary compounds, but it cannot be used on its own to make medical decisions. Because the evidence strength is limited and environmental triggers like smoking, oral contraceptives, and diet exert profound effects on CYP1A2 enzyme levels, genotype alone does not dictate absolute metabolism speed. Individuals should never initiate, discontinue, or alter dosages of any prescription medication based on personal genetic testing results. If you have questions about how your genetics may interact with specific pharmaceuticals, discuss them directly with your prescribing clinician or a pharmacogenomics specialist.
How common is this variant?
The rs1799834 variant is relatively common across global populations, with an overall minor allele frequency of approximately 0.30. Frequencies vary across continental ancestries in reference databases such as gnomAD and dbSNP.
Frequently asked questions
Does rs1799834 make me a slow caffeine metabolizer?
Not definitively. While rs1799834 is located in the CYP1A2 gene which processes caffeine, its individual impact on clearance speed is minor compared to well-established markers like rs762551. Personal factors such as cigarette smoking, oral contraceptive use, and overall liver health play a much larger role in daily caffeine clearance.
Can my rs1799834 genotype affect how my medications work?
The CYP1A2 enzyme processes several essential medications, but clinical guidelines such as CPIC do not recommend altering drug dosages based on rs1799834 alone. Because scientific evidence is limited, standard dosing should always be followed unless directed otherwise by your doctor or clinical pharmacist.
What is the difference between rs1799834 and the CYP1A2*1F allele?
The famous CYP1A2*1F haplotype is defined primarily by the promoter variant rs762551, which has strong evidence for altering enzyme inducibility. The rs1799834 SNP is a distinct marker within the same gene that is sometimes inherited alongside rs762551, but carries more limited independent scientific evidence.
Should I change how much coffee I drink based on this test?
No dietary changes are strictly necessary based on rs1799834 alone. How you feel after consuming caffeine—such as experiencing jitters, insomnia, or elevated heart rate—is a much more practical indicator of your personal tolerance than this single non-coding variant.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1799834?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29